🚨Very fortunate to be able to share these clinically important data at our oral presentation Society for Immunotherapy of Cancer SITC Early Career Scientist Committee OU Health Stephenson Cancer Center . Largest dataset on pts living with HIV and cancer #CATCH-IT consortium Amazinf team Talal El Zarif, MD Amin Nassar, MD Elio Adib and collaborators

Talented friends presenting their work at #SITC22 Giuseppe Lamberti Federica Pecci Alessandro Di Federico Mark Awad Society for Immunotherapy of Cancer

🙌🏻

KEAP1 mutations (mut) are heterogeneous in lung adenocarcinoma (LUAD). In this study out in Annals of Oncology we found that clonal KEAP1 mut w/ LOH have unique transcriptomic & immunophenotypic features, and are associated w/ #ICI resistance OncoAlert bit.ly/3BGBz3g 1/7

Comprehensive analysis ~1300pts treated w CT-IO on JTO & JTO CRR🎯Another piece led by the stellar Dana-Farber lung team João Alessi, MD @BiagioMd Mark Awad⚡️David James Pinato 🇺🇦 @ArielleElkrief Victor Vaz, MD Giuseppe Lamberti Gonzalo Recondo Deepti Venkatraman, MPH Federica Pecci jto.org/article/S1556-…

Excited to be heading to Santa Monica for #TTLC with our research group! Very thankful to work with such kind and talented individuals every day Dana-Farber

The IASLC's #TTLC23 Best Fellows Oral Abstract Session is going on now, with Drs. Lamberti, Cooper, Cheunkarndee and Lei Deng, MD (He/Him). #LCSM

In this retrospective series, Giuseppe Lamberti et al reported on intracranial activity of sotorasib in pts w/ #KRAS G12C mut #NSCLC ➡️ fal.cn/3ws9N @Oncoalert Mark Awad #LCSM #JCOPO

Just published! Great collaboration with Prof Lauren Averett Byers, MD and Prof Andrea Ardizzoni's Teams, led by Dr Laura Moliner Novel therapeutic strategies for recurrent SCLC. OncoAlert Division of Cancer Sciences @TheChristieSoO BTOG Mathew Carter sciencedirect.com/science/articl…

What to do in SCLC after progression to 1st line? 💊 Our review focus in current and - hopefully 🤞- future options for these patients. Many thanks to the rest of the team: Bingnan Zhang Giuseppe Lamberti Raffaele Califano Lauren Averett Byers, MD and Prof Ardizzoni bit.ly/3VGix5P #LCSM #SCLC

Taking a moment to appreciate all the amazing people behind this study out today Journal of Clinical Oncology that has been in the works for 2+ years. Hoping that it can guide oncologists caring for people living w/ #HIV and #cancer. ascopubs.org/doi/abs/10.120…

Thanks Clinical Cancer Research for featuring our work on the clinico-genomic landscape of #ATM mutations in #NSCLC on this month’s cover! W/@ArielleElkrief João Alessi, MD Xinan Wang Dana-Farber News Memorial Sloan Kettering Cancer Center OncoAlert #LCSM Read more about this effort here: shorturl.at/bjlX2

In a new study published in Journal of Clinical Oncology, Mark Awad, @BiagioRicciutiMD, and Giuseppe Lamberti Dana-Farber have uncovered mechanisms of resistance to immunotherapy in metastatic non-small-cell lung cancer. Research Summary ▶️ ms.spr.ly/6013ioykh

I hope this finding will pave the way to new treatment options and outcome improvements for all patients. Thanks to the incredible team work with Biagio Ricciuti, MD PhD and the terrific mentorship by Mark Awad!

Our NEW Primer on Gastric neuroendocrine neoplasms is live today! By Giuseppe Lamberti, Panzuto, Pavel, O’Toole, Ambrosini, Falconi, Garcia-Carbonero, Rachel Riechelmann, Rindi & Campana. Check it out here: go.nature.com/4aHikWE

A pleasure meeting with 2 brilliant minds @aiom Dana-Farber group and such wonderful hosts. Grazie ! See you soon. #Aiom #Asco #Esmo #Oncology #ClinicalResearch #ResidentLife

🔥 A must-read review pertaining to "tumor mutational burden" , which is a predictor of response to PD(L)-1 inhibition 🎯 ⭐️🔥✅Key points that should be kept in mind in terms of using TMB in clinical practice:🚨 🧬TMB is estimated using next-generation sequencing (NGS), whole

In metastatic non-small cell lung cancer treated w/ First-line pembrolizumab 🧪and cemiplimab ✅ PD-L1 expression ≥9⃣0⃣%, had significant3⃣year survival benefits 🆚 those with PD-L1 expression levels of 50-89% Highlighting the potential for personalized treatment approaches

💫 Just out our collaborative work suggesting that adding temozolomide to capecitabine (CAPTEM) 💊 may improve outcomes 📈 in patients with atypical carcinoids 🫁 🤩 Thanks to all the Authors (and friends) for their invaluable efforts Springer Nature rdcu.be/d7rjm

📯Just out: our Italian 🇮🇹 multicenter phase II trial of beva+atezo+PE in first-line ES-SCLC 🎯 1ary endpoint of OS met 📌Beva confirms PFS benefit in ES-SCLC 👀 on toxicity 🙏🏻 Thanks to all pts and caregivers Thanks to all investigators Università di Bologna #SCLC #lungcancer